Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBIG in HBV-related HCC
NCT05293158Not yet recruiting
- Sponsor
- Medical University of Graz
- Start
- Nov 2024
- Primary completion
- Jun 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
01
Overview
Open-label, single-arm trial of hepatitis B immune globulin in hepatocellular carcinoma (HCC), sponsored by Medical University of Graz. Primary endpoint: HBsAg change from baseline to week 6. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
hepatitis B immune globulin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05293158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05293158.